← Eichor
Study identifier: NCT06609980 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Restoration of Antibiotics Related Infant Microbiota Perturbations by Autologous Fecal Transplant

Condition: Antibiotic Treatment  ·  Sponsor: Rutgers, The State University of New Jersey

PhasePhase 1
Planned participants100
Who can joinAll sexes, 1 Month to 4 Years
Healthy volunteersYes

About this study

Antibiotics are lifesaving therapeutic drugs which have been used by adults, children, and infants alike for decades. There is an increase in global use of antibiotics over the course of lifetime and earlier in lifetime, with some countries recording as high as 12 courses a year in children younger than two. While antibiotics are successful in eradicating many pathogenic bacteria, research has demonstrated significant effect on beneficial gut microbiota, including long-lasting shift in the dynamics, composition, richness, and maturity of the intestinal flora. Microbiota alterations during early life, including through antibiotics use as well as birth via C-section, constitute a developmental perturbation, which increases the risk of modern diseases of immune and metabolic dysfunction. Strong epidemiological evidence suggests associations between early stressors of the microbiota and a number of common diseases, such as obesity, asthma, allergies, celiac disease, and Type 1 Diabetes. Furthermore, excess antibiotic exposure is associated with the development of neurological and psychiatric disorders. Currently, no strategies exist to restore the microbiome other than reliance on spontaneous repair mechanism, which often takes months in a healthy individual barring further antibiotic exposure. Contrary to popular belief, ingestion of probiotics, particularly after antibiotics, has been demonstrated to slow down the repair as it introduces an exogenous and massive amounts of only…

This description comes directly from the study's public registry record.

Talk to the study team

Maria Gloria Dominguez-Bello, PhD  ·  848-932-5648  ·  md1360@sebs.rutgers.edu

Anna Dulencin, PhD  ·  (848) 932-8309  ·  anna.dulencin@eagleton.rutgers.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Rutgers Department of Biochemistry & MicrobiologyNew Brunswick, New Jersey, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06609980